title: Potential new treatments for diabetic kidney disease.
abstract: Antifibrotic agents, antioxidant agents, ET-a receptor antagonists, and a few other agents with nonspecific or multifaceted mechanisms of action have been evaluated and progressed to small clinical studies in human subjects. Although there are limited data at the present time, these early evaluations have produced some favorable results that at least warrant further investigation. There is certainly not enough compelling evidence to justify the routine use of any of these products specifically for DKD at the moment; however, more well-controlled and adequately powered studies in several hundred patients will help determine which of these may have a place in the DKD treatment armamentarium of the future.
authors.affiliation: Purdue University College of Pharmacy, West Lafayette, IN 47907-2091, USA.
authors.forename: Deanna S
authors.initials: DS
authors.lastname: Kania
authors.forename: Cory T
authors.initials: CT
authors.lastname: Smith
authors.forename: Christy L
authors.initials: CL
authors.lastname: Nash
authors.forename: Jasmine D
authors.initials: JD
authors.lastname: Gonzalvo
authors.forename: Andrea
authors.initials: A
authors.lastname: Bittner
authors.forename: Brian M
authors.initials: BM
authors.lastname: Shepler
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000493:pharmacokinetics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D000975:Antioxidants / Q000493:pharmacokinetics / Q000627:therapeutic use; D001682:Biological Availability; D002986:Clinical Trials as Topic; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D065128:Endothelin Receptor Antagonists; D016166:Free Radical Scavengers / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D054539:Medication Therapy Management; D017466:Receptors, Endothelin / Q000378:metabolism; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents; D000975:Antioxidants; D065128:Endothelin Receptor Antagonists; D016166:Free Radical Scavengers; D017466:Receptors, Endothelin; D014409:Tumor Necrosis Factor-alpha